2021
Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
Singh S, Heien HC, Herrin J, Dulai PS, Sangaralingham L, Shah ND, Sandborn WJ. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology And Hepatology 2021, 20: e74-e88. PMID: 33640480, PMCID: PMC8384969, DOI: 10.1016/j.cgh.2021.02.032.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseSerious infectionsMarginal structural Cox proportional hazards modelsCox proportional hazards modelBaseline disease characteristicsRetrospective cohort studyAdministrative claims databaseProportional hazards modelTime-varying useCohort studyBowel diseaseTreatment initiationUlcerative colitisHealthcare utilizationClaims databaseDisease characteristicsTumor necrosisVedolizumabLower riskHazards modelPatientsInfectionAntagonistInsurance coverageRisk
2020
S0861 Comparative Risk of Serious Infections With Tumor Necrosis Factor-α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
Singh S, Heien H, Herrin J, Dulai P, Sangaralingham L, Shah N, Sandborn W. S0861 Comparative Risk of Serious Infections With Tumor Necrosis Factor-α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. The American Journal Of Gastroenterology 2020, 115: s444-s445. DOI: 10.14309/01.ajg.0000705492.87799.ce.Peer-Reviewed Original Research